A novel approach to tackling obesity-induced diabetes has received a significant boost with the announcement that Sagar Bapat, MD, PhD, has been awarded a 2026 Pathway to Stop Diabetes Award from the American Diabetes Association (ADA). Bapat, an Assistant Professor at the University of California, San Francisco (UCSF), is pioneering a living T cell-based therapy designed to enhance the body’s ability to burn energy, offering a potentially preventative intervention against type 2 diabetes. This research represents a promising new direction in the fight against a disease affecting millions and is fueled by a $11.3 million investment from the ADA in seven groundbreaking projects.
The rising prevalence of obesity and its link to type 2 diabetes is a major public health concern. According to the Centers for Disease Control and Prevention, over 37 million Americans have diabetes, and approximately 96 million adults have prediabetes. Bapat’s function focuses on harnessing the power of the immune system to address the root causes of metabolic dysfunction. His team aims to engineer regulatory T cells (Tregs) – a type of immune cell – to specifically target and transform energy-storing adipose tissue into energy-burning tissue. This innovative strategy could potentially reverse or prevent obesity and insulin resistance, offering a durable solution beyond traditional treatments.
Engineering Immunity to Combat Metabolic Disease
Bapat’s research builds on the understanding that obesity isn’t simply a matter of excess energy storage, but a complex physiological condition. “Obesity is a manifestation of excessive storage of energy,” Bapat explained, “it could potentially be mitigated by turning on the body’s dormant systems for burning, not storing, that energy.” The team’s approach utilizes CRISPR technology alongside targeted cellular therapy to precisely modify Tregs, guiding them to deliver signals that promote a shift in adipose tissue function. This targeted approach aims to minimize off-target effects and maximize therapeutic benefit.
The Pathway to Stop Diabetes Award provides critical funding – five to seven years – for early-career scientists to pursue innovative research without the constraints of traditional project limitations. This allows researchers like Bapat to explore high-risk, high-reward ideas that might not otherwise receive support. “The Pathway award provides critical support to translate these insights into therapeutic strategies with the potential for long-term benefit for patients,” Bapat said.
A Collaborative Approach to Diabetes Research
The ADA’s commitment to fostering innovation is evident in the Pathway program. Awardees are not only provided with financial support but are too paired with renowned diabetes scientists who offer mentorship and guidance throughout their research journey. Rita Kalyani, the ADA’s chief scientific and medical officer, emphasized the importance of this collaborative environment. “Diabetes research is vital to improving the lives of people living with diabetes, and ultimately finding a cure,” Kalyani stated. “The ADA is proud to foster new medical breakthroughs and support early-career investigators who are conducting innovative, high-impact diabetes research. Congratulations to these pioneering scientists.”
Bapat’s work at UCSF builds on a strong foundation of research in cardiovascular health and metabolic disease. He earned his bachelor’s degree from Stanford University in 2009, followed by a combined MD-PhD from the University of California, San Diego and the Salk Institute for Biological Studies in 2017. He completed his residency in clinical pathology at UCSF in 2020, further solidifying his expertise in the field. His lab at UCSF is dedicated to developing novel immunotherapies for metabolic diseases.
The Potential of T Cell Therapy
The use of T cells in cancer immunotherapy has demonstrated remarkable success in recent years, inspiring researchers to explore their potential in other diseases, including diabetes. Bapat’s approach differs from traditional immunotherapy by focusing on regulatory T cells, which play a crucial role in suppressing the immune system and maintaining tolerance. By engineering these cells to promote metabolic health, he hopes to harness their regulatory power to restore healthy tissue function and improve insulin sensitivity. The initial research will focus on demonstrating efficacy in mouse models before progressing to human trials.
This research is particularly significant given the limitations of current diabetes treatments, which often focus on managing symptoms rather than addressing the underlying causes of the disease. A preventative therapy that could reverse or prevent obesity and insulin resistance would represent a major breakthrough in diabetes care. The $11.3 million investment from the ADA, distributed among seven researchers, underscores the organization’s commitment to supporting innovative research that has the potential to transform the lives of people living with diabetes.
The next steps for Bapat’s team involve refining the T cell engineering process and conducting preclinical studies to assess the safety and efficacy of the therapy in animal models. Results from these studies will be crucial in determining whether to move forward with human clinical trials. The ADA will continue to monitor the progress of the Pathway Award recipients and provide support as they advance their research.
This is an ongoing story. Share your thoughts and questions in the comments below.
Disclaimer: The information provided in this article is for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
